Intermittent androgen deprivation for locally advanced prostate cancer - Preliminary experience from an ongoing randomized controlled study of the South European Urooncological Group

F.C. Da Silva, A. Bono, P. Whelan, M. Brausi, M. Queimadelos, J. Portillo, Z. Kirkali, C. Robertson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Approximately 80% of prostate cancer patients achieve symptomatic and objective responses following androgen suppression, and serum prostate specific antigen (PSA) levels decrease in almost all patients. Surgical or medical castration results in a median progression-free survival of 12-33 months and a median overall survival of 23-37 months in patients with stage M1 disease. However, for reasons that remain unknown, the cell death process induced by androgen ablation, by whatever means, fails to eliminate the entire malignant cell population [1]. Another limitation of conventional androgen ablation is that it increases the rate of progression of prostate cancer to an androgen-independent state [1], and, after a variable period of time averaging 24 months, the tumor inevitably recurs with increasing serum PSA levels and is characterized by androgen-independent growth. Over the past 20 years, most efforts have focused on maximizing the degree of androgen suppression therapy by combining agents that inhibit or block both testicular and adrenal androgens. However, maximal androgen ablation increases treatment-related side effects and expenses, while prolonging disease-free interval by 3-6 months in most patients [2].
LanguageEnglish
Pages24-28
Number of pages4
JournalOncology
Volume65
Issue numberSupplement 1
DOIs
Publication statusPublished - 2003

Fingerprint

Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Castration
Serum
Disease-Free Survival
Cell Death
Survival
Therapeutics
Growth
Population
Neoplasms

Keywords

  • urology
  • cancer
  • prostate cancer
  • cancer research

Cite this

Da Silva, F.C. ; Bono, A. ; Whelan, P. ; Brausi, M. ; Queimadelos, M. ; Portillo, J. ; Kirkali, Z. ; Robertson, C. / Intermittent androgen deprivation for locally advanced prostate cancer - Preliminary experience from an ongoing randomized controlled study of the South European Urooncological Group. In: Oncology. 2003 ; Vol. 65, No. Supplement 1. pp. 24-28.
@article{093c0ad39037448eadad2bb2e71136ae,
title = "Intermittent androgen deprivation for locally advanced prostate cancer - Preliminary experience from an ongoing randomized controlled study of the South European Urooncological Group",
abstract = "Approximately 80{\%} of prostate cancer patients achieve symptomatic and objective responses following androgen suppression, and serum prostate specific antigen (PSA) levels decrease in almost all patients. Surgical or medical castration results in a median progression-free survival of 12-33 months and a median overall survival of 23-37 months in patients with stage M1 disease. However, for reasons that remain unknown, the cell death process induced by androgen ablation, by whatever means, fails to eliminate the entire malignant cell population [1]. Another limitation of conventional androgen ablation is that it increases the rate of progression of prostate cancer to an androgen-independent state [1], and, after a variable period of time averaging 24 months, the tumor inevitably recurs with increasing serum PSA levels and is characterized by androgen-independent growth. Over the past 20 years, most efforts have focused on maximizing the degree of androgen suppression therapy by combining agents that inhibit or block both testicular and adrenal androgens. However, maximal androgen ablation increases treatment-related side effects and expenses, while prolonging disease-free interval by 3-6 months in most patients [2].",
keywords = "urology, cancer, prostate cancer, cancer research",
author = "{Da Silva}, F.C. and A. Bono and P. Whelan and M. Brausi and M. Queimadelos and J. Portillo and Z. Kirkali and C. Robertson",
year = "2003",
doi = "10.1159/000072488",
language = "English",
volume = "65",
pages = "24--28",
journal = "Oncology",
issn = "0030-2414",
number = "Supplement 1",

}

Intermittent androgen deprivation for locally advanced prostate cancer - Preliminary experience from an ongoing randomized controlled study of the South European Urooncological Group. / Da Silva, F.C.; Bono, A.; Whelan, P.; Brausi, M.; Queimadelos, M.; Portillo, J.; Kirkali, Z.; Robertson, C.

In: Oncology, Vol. 65, No. Supplement 1, 2003, p. 24-28.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intermittent androgen deprivation for locally advanced prostate cancer - Preliminary experience from an ongoing randomized controlled study of the South European Urooncological Group

AU - Da Silva, F.C.

AU - Bono, A.

AU - Whelan, P.

AU - Brausi, M.

AU - Queimadelos, M.

AU - Portillo, J.

AU - Kirkali, Z.

AU - Robertson, C.

PY - 2003

Y1 - 2003

N2 - Approximately 80% of prostate cancer patients achieve symptomatic and objective responses following androgen suppression, and serum prostate specific antigen (PSA) levels decrease in almost all patients. Surgical or medical castration results in a median progression-free survival of 12-33 months and a median overall survival of 23-37 months in patients with stage M1 disease. However, for reasons that remain unknown, the cell death process induced by androgen ablation, by whatever means, fails to eliminate the entire malignant cell population [1]. Another limitation of conventional androgen ablation is that it increases the rate of progression of prostate cancer to an androgen-independent state [1], and, after a variable period of time averaging 24 months, the tumor inevitably recurs with increasing serum PSA levels and is characterized by androgen-independent growth. Over the past 20 years, most efforts have focused on maximizing the degree of androgen suppression therapy by combining agents that inhibit or block both testicular and adrenal androgens. However, maximal androgen ablation increases treatment-related side effects and expenses, while prolonging disease-free interval by 3-6 months in most patients [2].

AB - Approximately 80% of prostate cancer patients achieve symptomatic and objective responses following androgen suppression, and serum prostate specific antigen (PSA) levels decrease in almost all patients. Surgical or medical castration results in a median progression-free survival of 12-33 months and a median overall survival of 23-37 months in patients with stage M1 disease. However, for reasons that remain unknown, the cell death process induced by androgen ablation, by whatever means, fails to eliminate the entire malignant cell population [1]. Another limitation of conventional androgen ablation is that it increases the rate of progression of prostate cancer to an androgen-independent state [1], and, after a variable period of time averaging 24 months, the tumor inevitably recurs with increasing serum PSA levels and is characterized by androgen-independent growth. Over the past 20 years, most efforts have focused on maximizing the degree of androgen suppression therapy by combining agents that inhibit or block both testicular and adrenal androgens. However, maximal androgen ablation increases treatment-related side effects and expenses, while prolonging disease-free interval by 3-6 months in most patients [2].

KW - urology

KW - cancer

KW - prostate cancer

KW - cancer research

UR - http://dx.doi.org/10.1159/000072488

U2 - 10.1159/000072488

DO - 10.1159/000072488

M3 - Article

VL - 65

SP - 24

EP - 28

JO - Oncology

T2 - Oncology

JF - Oncology

SN - 0030-2414

IS - Supplement 1

ER -